Treats Moderate. ANDA 210612, held by Novast Labs. Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 210612 (Estradiol And Norethindrone Acetate), held by Novast Labs, was first approved by FDA on Apr 3, 2019, with 2 approved supplements and 0 published complete response letters.
Estradiol and norethindrone acetate tablets are an estrogen and progestin combination indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitations of Use: When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. Prevention of Postmenopausal Osteoporosis Limitations of Use: When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 3, 2019 | Original application | Approved | None posted |
| Estradiol And Norethindrone Acetate0.5MG;0.1MG · tablet;oral | Estradiol; Norethindrone Acetate | Rx |
| Estradiol And Norethindrone Acetate1MG;0.5MG · tablet;oral | Estradiol; Norethindrone Acetate | Rx |
| May 31, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 18, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 3, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters